Key points – Treatment options for relapsed/refractory PMBCL are limited, and prognosis is generally poor. Pembrolizumab had a manageable safety profile and promising antitumor activity in heavily pretreated PMBCL patients.
Home / Resource Library / Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma